DOP75 Effectiveness and Safety of tofacitinib versus vedolizumab in Patients with Ulcerative Colitis; A Nationwide, ICC Registry study
Tessa Straatmijer(Leiden University Medical Center), Marjolijn Duijvestein(Amsterdam University Medical Centers), M D J Wolvers(Amsterdam University Medical Centers), Andrica de Vries(Erasmus MC), Bas Oldenburg(University Medical Center Utrecht), Nidhi Srivastava, Marieke Pierik(Maastricht University Medical Centre), Frank Hoentjen(Radboud University Nijmegen), Alexander Bodelier(Amphia Ziekenhuis), Cyriel Y. Ponsioen(Amsterdam UMC Location University of Amsterdam), Carmen S. Horjus(Rijnstate Hospital), Marijn C. Visschedijk(University Medical Center Groningen), Gerard Dijkstra(University Medical Center Groningen), Bindia Jharap(Meander Medisch Centrum), Tessa E H Römkens(Jeroen Bosch Ziekenhuis), C. Janneke van der Woude(Radboud University Nijmegen), Rachel West(Sint Franciscus Gasthuis), Jeroen M. Jansen(OLVG), M M van der Voorn(Haga Hospital), Ad A. van Bodegraven(Vrije Universiteit Amsterdam), Nanne K.H. de Boer, Wout Mares(Ziekenhuis Gelderse Vallei), Eleonora A. Festen(University Medical Center Groningen)
Cited by 0
Related Papers
Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial
|The Lancet|2017|732
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
|Clinical and Translational Gastroenterology|2016|724
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
|Gastroenterology|2015|478